[go: up one dir, main page]

MX2019008722A - Proteínas de unión al receptor de glucagón y métodos para usarlas. - Google Patents

Proteínas de unión al receptor de glucagón y métodos para usarlas.

Info

Publication number
MX2019008722A
MX2019008722A MX2019008722A MX2019008722A MX2019008722A MX 2019008722 A MX2019008722 A MX 2019008722A MX 2019008722 A MX2019008722 A MX 2019008722A MX 2019008722 A MX2019008722 A MX 2019008722A MX 2019008722 A MX2019008722 A MX 2019008722A
Authority
MX
Mexico
Prior art keywords
methods
binding proteins
glucagon receptor
receptor binding
glucagon
Prior art date
Application number
MX2019008722A
Other languages
English (en)
Inventor
Wang Yan
Shen Wenyan
Matern Hugo
Liu Zhonghao
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of MX2019008722A publication Critical patent/MX2019008722A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona proteínas de unión, tales como anticuerpos, que se unen a receptores de glucagón, que incluyen un receptor de glucagón humano y métodos para su uso.
MX2019008722A 2017-01-27 2018-01-26 Proteínas de unión al receptor de glucagón y métodos para usarlas. MX2019008722A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762451603P 2017-01-27 2017-01-27
PCT/US2018/015452 WO2018140729A1 (en) 2017-01-27 2018-01-26 Glucagon receptor binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2019008722A true MX2019008722A (es) 2019-10-02

Family

ID=62979257

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008722A MX2019008722A (es) 2017-01-27 2018-01-26 Proteínas de unión al receptor de glucagón y métodos para usarlas.

Country Status (18)

Country Link
US (3) US10995145B2 (es)
EP (1) EP3573651A4 (es)
JP (1) JP7005638B2 (es)
KR (1) KR102627311B1 (es)
CN (1) CN110520151B (es)
AU (1) AU2018213374B2 (es)
BR (1) BR112019015479A2 (es)
CA (1) CA3048913A1 (es)
CL (1) CL2019002081A1 (es)
CO (1) CO2019009035A2 (es)
IL (1) IL267638B2 (es)
MX (1) MX2019008722A (es)
MY (1) MY201301A (es)
PE (1) PE20191404A1 (es)
PH (1) PH12019501605A1 (es)
SG (1) SG11201906682YA (es)
UA (1) UA129078C2 (es)
WO (1) WO2018140729A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019015479A2 (pt) 2017-01-27 2020-03-31 Ngm Biopharmaceuticals, Inc. Anticorpo e seu uso, célula, composição, molécula polinucleotídica, vetor, método para inibir a sinalização de gcgr, método para reduzir ou baixar os níveis de glicose, método para aumentar o nível de peptídeo c, método para aumentar o nível de insulina, método para tratar diabetes, método para tratar hiperglicemia, método para tratar uma doença, método para melhorar a função das células
US10961315B2 (en) 2018-07-27 2021-03-30 Ngm Biopharmaceuticals, Inc. Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody
TW202024134A (zh) * 2018-12-21 2020-07-01 大陸商江蘇恆瑞醫藥股份有限公司 雙特異性蛋白
US11633488B2 (en) * 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
WO2022083720A1 (zh) * 2020-10-23 2022-04-28 江苏恒瑞医药股份有限公司 Glp1-gcgr抗体融合蛋白变体及包含其的组合物
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK580789D0 (da) 1989-11-20 1989-11-20 Novo Nordisk As Fremgangsmaade til oprensning af polypeptider
NZ255922A (en) 1992-08-28 1998-01-26 Zymogenetics Inc Glucagon receptor, dna constructs and host cells therefor
US5776725A (en) 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
US20040037826A1 (en) 2002-06-14 2004-02-26 Michelsen Birgitte Koch Combined use of a modulator of CD3 and a GLP-1 compound
WO2006005469A2 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
MX2010003329A (es) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de il-6.
EP2214711B1 (en) 2007-10-25 2018-08-15 Trellis RSV Holdings, Inc. Anti-rsv g protein antibodies
PE20091674A1 (es) * 2008-03-27 2009-11-04 Lilly Co Eli Antagonistas del receptor de glucagon
RU2521669C2 (ru) 2008-10-31 2014-07-10 Торэй Индастриз, Инк. Способ иммунологического анализа белка cxcl1 человека
WO2011030935A1 (en) 2009-09-08 2011-03-17 Neopharm Co., Ltd. Antibodies against glucagon receptor and their use
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
WO2013059531A1 (en) * 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
US9934913B2 (en) 2011-10-26 2018-04-03 Nokia Technologies Oy Apparatus and associated methods
US20140275368A1 (en) 2013-03-14 2014-09-18 Sabic Innovative Plastics Ip B.V. Blended polymer compositions with improved mold release properties
CA2911412A1 (en) * 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
CN104231083A (zh) * 2013-06-09 2014-12-24 杭州鸿运华宁生物医药工程有限公司 抗胰高血糖素受体的抗体及其用途
WO2015154795A1 (en) 2014-04-08 2015-10-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Combination therapy for the treatment of autoimmune diseases
AU2015273199B2 (en) * 2014-06-08 2020-09-10 REMD Biotherapeutics, Inc Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
AU2015317899A1 (en) * 2014-09-16 2017-04-06 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof
CN107614695B (zh) 2015-04-02 2022-01-25 瑞美德生物医药科技有限公司 用胰高血糖素受体拮抗性抗体治疗肥胖症和非酒精性脂肪肝病或非酒精性脂肪性肝炎的方法
WO2017040986A1 (en) 2015-09-04 2017-03-09 Remd Biotherapeutics, Inc. Methods for treating heart failure using glucagon receptor antagonistic antibodies
US20190062441A1 (en) 2015-10-07 2019-02-28 Remd Biotherapeutics, Inc. Methods For Treating Rare Genetic Disorders Using Glucagon Receptor Antagonistic Antibodies
US20190002577A1 (en) 2016-01-04 2019-01-03 Remd Biotherapeutics, Inc. Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies
WO2018075792A1 (en) 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
BR112019015479A2 (pt) 2017-01-27 2020-03-31 Ngm Biopharmaceuticals, Inc. Anticorpo e seu uso, célula, composição, molécula polinucleotídica, vetor, método para inibir a sinalização de gcgr, método para reduzir ou baixar os níveis de glicose, método para aumentar o nível de peptídeo c, método para aumentar o nível de insulina, método para tratar diabetes, método para tratar hiperglicemia, método para tratar uma doença, método para melhorar a função das células
US10961315B2 (en) 2018-07-27 2021-03-30 Ngm Biopharmaceuticals, Inc. Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody

Also Published As

Publication number Publication date
RU2019126781A3 (es) 2021-10-27
MY201301A (en) 2024-02-15
PH12019501605A1 (en) 2020-06-01
CN110520151B (zh) 2024-04-12
IL267638B2 (en) 2025-08-01
JP2020506692A (ja) 2020-03-05
CL2019002081A1 (es) 2019-12-20
US10995145B2 (en) 2021-05-04
AU2018213374B2 (en) 2024-09-05
US20210332144A1 (en) 2021-10-28
CA3048913A1 (en) 2018-08-02
PE20191404A1 (es) 2019-10-04
EP3573651A1 (en) 2019-12-04
JP7005638B2 (ja) 2022-02-04
US20240084023A1 (en) 2024-03-14
CN110520151A (zh) 2019-11-29
IL267638A (en) 2019-08-29
SG11201906682YA (en) 2019-08-27
CO2019009035A2 (es) 2020-01-17
NZ754886A (en) 2024-04-26
RU2019126781A (ru) 2021-03-01
KR20190113815A (ko) 2019-10-08
WO2018140729A1 (en) 2018-08-02
EP3573651A4 (en) 2020-10-14
KR102627311B1 (ko) 2024-01-22
IL267638B1 (en) 2025-04-01
AU2018213374A1 (en) 2019-07-11
US20180273629A1 (en) 2018-09-27
UA129078C2 (uk) 2025-01-08
US11732049B2 (en) 2023-08-22
BR112019015479A2 (pt) 2020-03-31

Similar Documents

Publication Publication Date Title
MX2024011328A (es) Proteinas de union gfral y uso de las mismas
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
CO2019009035A2 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
CL2018000479A1 (es) Linfoopeitina strimal tomica (tslp) - anticuerpos de union y metodos de uso de los anticuerpos
CR20170262A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
UY37083A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso
CL2016002460A1 (es) Anticuerpos biespecíficos que se unen a cd38 y cd3
CR20150502A (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
CR20140585A (es) Proteinas de union a antigeno st2
MX2020003512A (es) Anticuerpos biespecificos anti-hapteno/anti-receptor de barrera hematoencefalica, complejos de los mismos y su uso como transportadores a traves de la barrera hematoencefalica.
MX2013013832A (es) Proteínas de unión receptoras fc.
CL2016001723A1 (es) Molécula de anticuerpo que se une al receptor de muerte programada 1 (pd-1) y usos.
MX2017001597A (es) Anticuerpos anti-pd-l1.
MX2016006709A (es) Moduladores de aplnr y usos de estos.
MX2016016886A (es) Anticuerpos anti-axl.
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
MA39708A (fr) Anticorps qui se lient au récepteur cannabinoïde 1 (cb1) humain
MX2021013207A (es) Neutralizacion del virus chikungunya mediada por anticuerpos.
CO2019013718A2 (es) Anticuerpos anti-trkb
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
BR112018004733A2 (pt) anticorpos do receptor de transferrina humana/ a-beta anti-humana biespecíficos e métodos de uso